Evidence map›Paper›PMID 37527465›Full record

ArticleBrain : a journal of neurology2023

Repeated mild traumatic brain injury triggers pathology in asymptomatic C9ORF72 transgenic mice.

Aydan Kahriman, James Bouley, Idil Tuncali, Elif O Dogan, Mariana Pereira, Thuyvan Luu, Daryl A Bosco, Samer Jaber, Owen M Peters, Robert H Brown and 1 more

Open access · greenAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Challenges of modelling TDP-43 pathology in mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Neurotrauma: 2024 update.Free neuropathology · 2024
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Aydan KahrimanDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
James BouleyDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Idil TuncaliDepartment of Psychological and Brain Sciences, University of Massachusetts, Amherst, MA 01003, USA.
Elif O DoganDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Mariana PereiraDepartment of Psychological and Brain Sciences, University of Massachusetts, Amherst, MA 01003, USA.
Thuyvan LuuDepartment of Molecular Medicine, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Daryl A BoscoDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-3735-3729
Samer JaberDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Owen M PetersSchool of Biosciences, UK Dementia Research Institute, Cardiff University, Cardiff, CF24 4HQ, UK.ORCID 0000-0002-6824-0663
Robert H BrownDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.
Nils HenningerDepartment of Neurology, University of Massachusetts Chan Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-3883-5623
University of Massachusetts Chan Medical School · USUniversity of Massachusetts Amherst · USUK Dementia Research Institute · GB

Funding

Expanding the chemical diversity of therapeutic oligonucleotides to treat neurodegenerative disordersR01NS104022 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ANASTASIA KHVOROVA · 2017 to 2026
$6.0M
Next-generation antisense therapeutics for ALS and frontotemporal dementiaR01NS111990 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Robert H Brown, Jonathan K Watts · 2019 to 2026
$5.2M
Innate Immunity Training ProgramT32AI095213 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SILVERMAN, NEAL · 2011 to 2025
$2.5M
Silencing C9or72 with rAAV Mediated RNAiR01NS088689 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BROWN, ROBERT H., MUELLER, CHRISTIAN · 2014 to 2017
$1.6M
Inhibiting axon degeneration in a mouse model of acute brain injury through deletion of Sarm1K08NS091499 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HENNINGER, NILS · 2016 to 2020
$919k
Role of Sarm1 in TBI-accentuated C9orf72 Frontotemporal DementiaR21NS131756 · NINDS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI HENNINGER, NILS · 2023 to 2024
$461k
Medical Research Council MC_PC_16030/2Medical Research Council MR/W004879/1NIAID NIH HHS T32 AI095213NINDS NIH HHS K08 NS091499NINDS NIH HHS R01 NS088689NINDS NIH HHS R01 NS104022NINDS NIH HHS R01 NS111990NINDS NIH HHS R21 NS131756
6 · The paper itself

Abstract

Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are fatal neurodegenerative diseases that represent ends of the spectrum of a single disease. The most common genetic cause of FTD and ALS is a hexanucleotide repeat expansion in the C9orf72 gene. Although epidemiological data suggest that traumatic brain injury (TBI) represents a risk factor for FTD and ALS, its role in exacerbating disease onset and course remains unclear. To explore the interplay between traumatic brain injury and genetic risk in the induction of FTD/ALS pathology we combined a mild repetitive traumatic brain injury paradigm with an established bacterial artificial chromosome transgenic C9orf72 (C9BAC) mouse model without an overt motor phenotype or neurodegeneration. We assessed 8-10 week-old littermate C9BACtg/tg (n = 21), C9BACtg/- (n = 20) and non-transgenic (n = 21) mice of both sexes for the presence of behavioural deficits and cerebral histopathology at 12 months after repetitive TBI. Repetitive TBI did not affect body weight gain, general neurological deficit severity, nor survival over the 12-month observation period and there was no difference in rotarod performance, object recognition, social interaction and acoustic characteristics of ultrasonic vocalizations of C9BAC mice subjected to repetitive TBI versus sham injury. However, we found that repetitive TBI increased the time to the return of the righting reflex, reduced grip force, altered sociability behaviours and attenuated ultrasonic call emissions during social interactions in C9BAC mice. Strikingly, we found that repetitive TBI caused widespread microglial activation and reduced neuronal density that was associated with loss of histological markers of axonal and synaptic integrity as well as profound neuronal transactive response DNA binding protein 43 kDa mislocalization in the cerebral cortex of C9BAC mice at 12 months; this was not observed in non-transgenic repetitive TBI and C9BAC sham mice. Our data indicate that repetitive TBI can be an environmental risk factor that is sufficient to trigger FTD/ALS-associated neuropathology and behavioural deficits, but not paralysis, in mice carrying a C9orf72 hexanucleotide repeat expansion.

Indexed as

Amyotrophic Lateral SclerosisBrain ConcussionC9orf72 ProteinFrontotemporal DementiaPick Disease of the BrainAnimalsDNA Repeat ExpansionFemaleMaleMiceMice, TransgenicC9orf72 Proteinamyotrophic lateral sclerosisC9orf72frontotemporal dementianeurodegenerationtransactive response DNA binding protein 43 kDa (TDP-43)

Identifiers

PMID37527465
PMCPMC11046056
OpenAlexW4385443497

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.